Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Takeda Begins Phase IIb Clinical Trial Of Norovirus Vaccine

XTALKS VITALS NEWS

Vaccine

According to Takeda, an earlier clinical trial of the norovirus vaccine found that the drug was well tolerated among the 98 trial participants, but did not significantly reduce diarrhea or vomiting symptoms.

Share this!

June 22, 2016 | by Sarah Massey, M.Sc.

The only vaccine currently in development to prevent norovirus infection has just entered a Phase IIb clinical trial. The developer of the vaccine – Takeda Pharmaceuticals – has started dosing patients to assess the efficacy of the norovirus vaccine candidate.

Tweet: Takeda Pharmaceuticals is dosing patients with #norovirus vaccine candidate http://ctt.ec/GIkYD+

Norovirus is a highly-infectious intestinal illness which leads to diarrhea and vomiting. Much like other infectious diseases that cause these symptoms, norovirus can cause severe dehydration which has the potential to be fatal.

The Japan-based drugmaker’s intramuscular vaccine – known as TAK-214 – uses virus-like particles to mimic the antigen-coated surface of the norovirus. According to Takeda, an earlier clinical trial of the norovirus vaccine found that the drug was well tolerated among the 98 trial participants, but did not significantly reduce diarrhea or vomiting symptoms.

Norovirus is associated with approximately 20 percent of all cases of diarrheal disease worldwide, according to the Centers for Disease Control and Prevention (CDC). Their estimates suggest that the average person could expect to become ill from a norovirus infection between three and eight times in their lifetime.



As there is no approved drug to treat patients with norovirus, efforts have been focused on preventing transmission of the disease. Norovirus can be acquired from contact with infected individuals and contaminated food and surfaces.

Currently, there is no available vaccine to prevent norovirus infection. “We are excited to be on the frontline of development of a vaccine against norovirus,” said Rajeev Venkayya, president of Takeda Vaccines.

Around 3,400 participants will be enrolled in the Phase IIb clinical trial, according to Takeda. The company expects that the trial will run until August of 2017.


Keywords: Clinical Trials, Norovirus, Vaccine


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.